Virulence factors and integrons are associated with MDR and XDR phenotypes in nosocomial strains of Pseudomonas aeruginosa in a Venezuelan university hospital.
Anti-Bacterial Agents
/ pharmacology
Biofilms
/ growth & development
Drug Resistance, Multiple, Bacterial
Hospitals, University
Humans
Integrons
/ genetics
Intensive Care Units
Microbial Sensitivity Tests
Phenotype
Pseudomonas Infections
/ microbiology
Pseudomonas aeruginosa
/ drug effects
Venezuela
Virulence
Virulence Factors
/ genetics
Journal
Revista do Instituto de Medicina Tropical de Sao Paulo
ISSN: 1678-9946
Titre abrégé: Rev Inst Med Trop Sao Paulo
Pays: Brazil
ID NLM: 7507484
Informations de publication
Date de publication:
2019
2019
Historique:
received:
06
09
2018
accepted:
05
12
2019
entrez:
11
4
2019
pubmed:
11
4
2019
medline:
19
4
2019
Statut:
ppublish
Résumé
Multidrug resistance (MDR), virulence and transferable elements potentiate Pseudomonas aeruginosa's role as an opportunistic pathogen creating a high risk for public health. In this study, we evaluated the possible association of multidrug resistance, virulence factors and integrons with intrahospital P. aeruginosa strains isolated from patients at Cumana hospital, Venezuela. Relevant clinical-epidemiological data were collected to study 176 strains (2009-2016) isolated from different hospital units. Bacterial resistance was classified as susceptible, low-level resistant (LDR), multidrug resistant (MDR) and extensively drug-resistant (XDR). Most strains produced pyoverdine, DNase, gelatinase and hemolysin. Around 73% of the strains showed some type of movement. MDR and XDR strains increased from 2009 (24.2% and 4.8%, respectively) to 2016 (53.1% and 18.8%); while LDR decreased from 64.5% to 6.3%. The exoU and exoS genes were found in a significant number of strains (38.1 and 7.4%, respectively). Class I integrons were detected in 35.8% of the strains and the frequency was associated with resistance (42.9, 22.4, 41.4 and 61.9%, for susceptible, LDR, MDR and XDR, respectively). The MDR/XDR strains were positively associated with hemolysins and exoU, but negatively associated with bacterial twitching. MDR/XDR phenotypes were also associated with the Intensive Care Unit (ICU), septicemia, bronchial infection and diabetic foot ulcers, as well as long hospital stay (≥10 days) and previous antimicrobial treatment. High frequency of MDR/XDR strains and their association with class I integrons and virulence factors can increase the infection potential, as well as morbidity and mortality of patients attending this hospital and could spread infection to the community, creating a health risk for the region.
Identifiants
pubmed: 30970111
pii: S0036-46652019005000209
doi: 10.1590/S1678-9946201961020
pmc: PMC6453424
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Virulence Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e20Références
Microbiology. 2001 Oct;147(Pt 10):2659-69
pubmed: 11577145
Chemotherapy. 2002 Sep;48(4):164-7
pubmed: 12218262
Clin Microbiol Rev. 2002 Oct;15(4):647-79
pubmed: 12364374
Ann Intern Med. 2002 Nov 19;137(10):791-7
pubmed: 12435215
J Clin Microbiol. 2003 Aug;41(8):3526-31
pubmed: 12904350
J Bacteriol. 1957 Apr;73(4):590-1
pubmed: 13428699
Antimicrob Agents Chemother. 2004 Apr;48(4):1433-4
pubmed: 15047562
Infect Immun. 2004 Dec;72(12):6969-77
pubmed: 15557619
FEMS Immunol Med Microbiol. 2005 Jun 1;44(3):303-9
pubmed: 15907453
Rev Argent Microbiol. 2007 Jul-Sep;39(3):143
pubmed: 17987848
Microbiology. 2009 Apr;155(Pt 4):1050-7
pubmed: 19332807
Rev Chilena Infectol. 2009 Aug;26(4):336-41
pubmed: 19802400
Environ Microbiol. 2010 Jun;12(6):1621-9
pubmed: 20370819
Med Intensiva. 2011 Jan-Feb;35(1):41-53
pubmed: 21215489
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
Eur J Clin Microbiol Infect Dis. 2012 May;31(5):711-4
pubmed: 21814759
Clin Microbiol Infect. 2012 May;18(5):502-8
pubmed: 21851482
Int J Antimicrob Agents. 2011 Nov;38(5):398-402
pubmed: 21873033
Rev Panam Salud Publica. 2011 Dec;30(6):519-28
pubmed: 22358396
Enferm Infecc Microbiol Clin. 2012 Oct;30(8):492-9
pubmed: 22385639
Rev Soc Bras Med Trop. 2012 Dec;45(6):707-12
pubmed: 23295873
Enferm Infecc Microbiol Clin. 2013 Feb;31(2):108-13
pubmed: 23357654
Rev Esp Quimioter. 2013 Jun;26(2):97-102
pubmed: 23817645
Ann Clin Microbiol Antimicrob. 2013 Oct 21;12:29
pubmed: 24143920
Int J Mol Sci. 2013 Oct 18;14(10):20983-1005
pubmed: 24145749
Front Cell Infect Microbiol. 2013 Nov 14;3:75
pubmed: 24294593
Virulence. 2014 Feb 15;5(2):303-10
pubmed: 24398422
Am J Respir Crit Care Med. 2014 Aug 1;190(3):289-97
pubmed: 24937177
Appl Environ Microbiol. 2014 Nov;80(21):6724-32
pubmed: 25172852
Rev Inst Med Trop Sao Paulo. 2016;58:13
pubmed: 27007556
BMC Infect Dis. 2016 Mar 08;16 Suppl 1:92
pubmed: 27169367
Enferm Infecc Microbiol Clin. 2017 Dec;35(10):630-637
pubmed: 27480954
Rev Argent Microbiol. 1989 Jan-Mar;21(1):25-30
pubmed: 2748851
Biomedica. 2016 Feb 23;36(0):69-77
pubmed: 27622627
Braz J Microbiol. 2017 Apr - Jun;48(2):211-217
pubmed: 28034598
Ann Clin Microbiol Antimicrob. 2017 Jul 12;16(1):50
pubmed: 28701170
Rev Latinoam Microbiol. 1993 Apr-Jun;35(2):147-52
pubmed: 8209107